{
  "analysis_mode": "HISTORICAL_ONLY",
  "symbol": "APTA.L",
  "generated_at": "2026-01-12T05:21:38.360230Z",
  "top_card": {
    "ticker": "APTA.L",
    "company_name": "Aptamer Group PLC",
    "sector": "Healthcare",
    "market_cap_gbp": 26295539,
    "days_active": 511,
    "apex_score_100": 55,
    "confidence_score_100": 40,
    "ai_final_score_25": 11,
    "ai_strength": "MODERATE",
    "timing_regime": "EARLY_BUILD",
    "action": "WATCH",
    "thesis_one_liner": "WATCH - EARLY_BUILD timing with 55/100 opportunity score"
  },
  "enrichment": {
    "company_info": {
      "name": "Aptamer Group PLC",
      "sector": "Healthcare",
      "industry": "Biotechnology",
      "exchange": "LSE",
      "market": "AIM",
      "currency": "GBP",
      "risk_tier": "High Risk",
      "current_market_cap": 26295539,
      "current_close_price": 0.975
    },
    "basics": {
      "ticker": "APTA.L",
      "current_price": 0.975,
      "ath": 157.0,
      "atl": 0.2,
      "ath_date": "2022-01-05",
      "atl_date": "2024-07-24",
      "week_52_high": 1.57,
      "week_52_low": 0.231,
      "week_52_high_date": "2025-09-02",
      "week_52_low_date": "2025-04-23",
      "drawdown_from_ath_pct": 99.38,
      "data_start": "2021-12-22",
      "data_end": "2026-01-09",
      "total_bars": 1020
    },
    "latest_signal": {
      "date": "2024-08-16",
      "scan_date": "2026-01-09",
      "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
      "signal_color": "PURPLE",
      "price": 0.23,
      "drawdown_pct": 85.53,
      "ai_score": 9.0,
      "rsi": 38.9,
      "cycle_position": 0.0462,
      "holding_period_days": 511,
      "current_pnl_pct": 323.91,
      "rally_state": "pulling_back",
      "distance_from_high_pct": -25.0,
      "Rally_Count": 2,
      "days_since_last_high": 11,
      "last_high_date": "2025-12-31",
      "lock_in_reached": true,
      "lock_in_date": "2025-09-01",
      "best_rally_pct": 465.22
    },
    "best_historical_signal": {
      "signal_date": "2024-08-16",
      "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
      "signal_color": "PURPLE",
      "entry_price": 0.23,
      "peak_price": 1.57,
      "peak_date": "2025-09-02",
      "rally_pct": 582.61,
      "days_to_peak": 382,
      "ai_score": 9.0
    },
    "all_historical_signals": [
      {
        "signal_id": "APTA.L_2023-04-11",
        "signal_date": "2023-04-11",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 25.5,
        "current_price": 0.975,
        "current_return_pct": -96.18,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-04-12",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 1006,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-04-12",
        "signal_date": "2023-04-12",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 25.5,
        "current_price": 0.975,
        "current_return_pct": -96.18,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-04-13",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 1005,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-05",
        "signal_date": "2023-05-05",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.975,
        "current_return_pct": -92.5,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.43,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 982,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-09",
        "signal_date": "2023-05-09",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.975,
        "current_return_pct": -92.5,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.43,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 978,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-05-10",
        "signal_date": "2023-05-10",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 13.0,
        "current_price": 0.975,
        "current_return_pct": -92.5,
        "best_rally_pct": 34.62,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.43,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 977,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-06-12",
        "signal_date": "2023-06-12",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 9.0,
        "current_price": 0.975,
        "current_return_pct": -89.17,
        "best_rally_pct": 94.44,
        "best_rally_date": "2023-06-14",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -94.43,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 944,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-04",
        "signal_date": "2023-07-04",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 4.5,
        "current_price": 0.975,
        "current_return_pct": -78.33,
        "best_rally_pct": 11.11,
        "best_rally_date": "2023-07-07",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -80.5,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 922,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-07",
        "signal_date": "2023-07-07",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 5.0,
        "current_price": 0.975,
        "current_return_pct": -80.5,
        "best_rally_pct": 0.0,
        "best_rally_date": "2023-07-10",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": 0.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 919,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-17",
        "signal_date": "2023-07-17",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 4.25,
        "current_price": 0.975,
        "current_return_pct": -77.06,
        "best_rally_pct": 11.76,
        "best_rally_date": "2023-07-26",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -79.47,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 909,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-07-31",
        "signal_date": "2023-07-31",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 2.0,
        "current_price": 0.975,
        "current_return_pct": -51.25,
        "best_rally_pct": 23.0,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -60.37,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 895,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-01",
        "signal_date": "2023-08-01",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 2.25,
        "current_price": 0.975,
        "current_return_pct": -56.67,
        "best_rally_pct": 9.33,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -60.37,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 894,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-02",
        "signal_date": "2023-08-02",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 2.0,
        "current_price": 0.975,
        "current_return_pct": -51.25,
        "best_rally_pct": 23.0,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -60.37,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 893,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-03",
        "signal_date": "2023-08-03",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 2.25,
        "current_price": 0.975,
        "current_return_pct": -56.67,
        "best_rally_pct": 9.33,
        "best_rally_date": "2023-08-08",
        "rally_state": "accumulating",
        "Rally_Count": 0,
        "distance_from_high_pct": -60.37,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 892,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-17",
        "signal_date": "2023-08-17",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 1.3,
        "current_price": 0.975,
        "current_return_pct": -25.0,
        "best_rally_pct": 11.54,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 1,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 878,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-18",
        "signal_date": "2023-08-18",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 1.2,
        "current_price": 0.975,
        "current_return_pct": -18.75,
        "best_rally_pct": 20.83,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 877,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-21",
        "signal_date": "2023-08-21",
        "signal_type": "ENHANCED ULTRA CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.225,
        "current_price": 0.975,
        "current_return_pct": -20.41,
        "best_rally_pct": 18.37,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 874,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-23",
        "signal_date": "2023-08-23",
        "signal_type": "ENHANCED DEEP CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.2,
        "current_price": 0.975,
        "current_return_pct": -18.75,
        "best_rally_pct": 20.83,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 4,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 872,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-24",
        "signal_date": "2023-08-24",
        "signal_type": "ENHANCED ULTRA CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.225,
        "current_price": 0.975,
        "current_return_pct": -20.41,
        "best_rally_pct": 18.37,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 871,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-25",
        "signal_date": "2023-08-25",
        "signal_type": "ENHANCED EXTREME CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.25,
        "current_price": 0.975,
        "current_return_pct": -22.0,
        "best_rally_pct": 16.0,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 3,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 870,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-08-30",
        "signal_date": "2023-08-30",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.175,
        "current_price": 0.975,
        "current_return_pct": -17.02,
        "best_rally_pct": 23.4,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 5,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 865,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2023-09-04",
        "signal_date": "2023-09-04",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 1.125,
        "current_price": 0.975,
        "current_return_pct": -13.33,
        "best_rally_pct": 28.89,
        "best_rally_date": "2023-09-27",
        "rally_state": "accumulating",
        "Rally_Count": 2,
        "distance_from_high_pct": -32.76,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 860,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-01",
        "signal_date": "2024-02-01",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.9,
        "current_price": 0.975,
        "current_return_pct": 8.33,
        "best_rally_pct": 44.44,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 710,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-05",
        "signal_date": "2024-02-05",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.725,
        "current_price": 0.975,
        "current_return_pct": 34.48,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 706,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-06",
        "signal_date": "2024-02-06",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.725,
        "current_price": 0.975,
        "current_return_pct": 34.48,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 705,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-07",
        "signal_date": "2024-02-07",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.725,
        "current_price": 0.975,
        "current_return_pct": 34.48,
        "best_rally_pct": 79.31,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 7,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 704,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-02-21",
        "signal_date": "2024-02-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.625,
        "current_price": 0.975,
        "current_return_pct": 56.0,
        "best_rally_pct": 108.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 690,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-03-21",
        "signal_date": "2024-03-21",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.975,
        "current_return_pct": 69.57,
        "best_rally_pct": 126.09,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 661,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-03-28",
        "signal_date": "2024-03-28",
        "signal_type": "CRASH ZONE BOTTOM",
        "signal_color": "YELLOW",
        "entry_price": 0.575,
        "current_price": 0.975,
        "current_return_pct": 69.57,
        "best_rally_pct": 126.09,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 654,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-04-04",
        "signal_date": "2024-04-04",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.5,
        "current_price": 0.975,
        "current_return_pct": 95.0,
        "best_rally_pct": 160.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 647,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-24",
        "signal_date": "2024-07-24",
        "signal_type": "ULTRA CRASH BOTTOM",
        "signal_color": "RED",
        "entry_price": 0.25,
        "current_price": 0.975,
        "current_return_pct": 290.0,
        "best_rally_pct": 420.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 4,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 536,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-25",
        "signal_date": "2024-07-25",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.3,
        "current_price": 0.975,
        "current_return_pct": 225.0,
        "best_rally_pct": 333.33,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 3,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 535,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-07-26",
        "signal_date": "2024-07-26",
        "signal_type": "EXTREME CRASH BOTTOM",
        "signal_color": "ORANGE",
        "entry_price": 0.26,
        "current_price": 0.975,
        "current_return_pct": 275.0,
        "best_rally_pct": 400.0,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 534,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-08-14",
        "signal_date": "2024-08-14",
        "signal_type": "DEEP CRASH BOTTOM",
        "signal_color": "GREEN",
        "entry_price": 0.24,
        "current_price": 0.975,
        "current_return_pct": 306.25,
        "best_rally_pct": 441.67,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 515,
        "status": "historical"
      },
      {
        "signal_id": "APTA.L_2024-08-16",
        "signal_date": "2024-08-16",
        "signal_type": "ENHANCED CRASH CRASH-ACCUM COMBO",
        "signal_color": "PURPLE",
        "entry_price": 0.23,
        "current_price": 0.975,
        "current_return_pct": 323.91,
        "best_rally_pct": 465.22,
        "best_rally_date": "2025-09-01",
        "rally_state": "pulling_back",
        "Rally_Count": 2,
        "distance_from_high_pct": -25.0,
        "days_since_last_high": 11,
        "lock_in_reached": true,
        "age_days": 513,
        "status": "historical"
      }
    ],
    "stats": {
      "total_signals": 34,
      "win_rate_pct": 100.0,
      "avg_rally_pct": 147.74,
      "median_rally_pct": 94.44,
      "best_rally_pct": 582.61,
      "worst_rally_pct": 9.33
    },
    "splits": [],
    "split_risk": {
      "split_detected": false,
      "risk_level": "NONE",
      "confidence": "HIGH"
    },
    "data_quality": {
      "price_reliability": "RELIABLE",
      "pnl_reliability": "RELIABLE",
      "overall_confidence": "HIGH"
    },
    "risk_flags": [
      "EXTREME_DRAWDOWN",
      "FREQUENT_CRASHES"
    ],
    "last_updated": "2026-01-11 18:23:12 UTC"
  },
  "decision_summary": {
    "why_it_matters": [
      "APEX 55/100 indicates strong opportunity quality",
      "Timing regime: EARLY_BUILD",
      "Historical profile: 2 rallies, 465% best run"
    ],
    "main_risk": "Confidence 40/100 - full data loaded",
    "watch_next": [
      "RNS catalysts (funding/operational updates)",
      "Volume expansion confirmation",
      "Timing regime change signals"
    ]
  },
  "triangulation": {
    "rns": {
      "has_data": true,
      "ticker": "APTA.L",
      "latest": [
        {
          "title": "Aptamer signs licensing agreement with Alphazyme",
          "announcement_date": "23rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "23 Dec 2025 07:00\nRNS Number : 6368M\nAptamer Group PLC\n23 December 2025\n23 December 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAptamer signs licensing agreement with Alphazyme\nNon-exclusive OEM license for enzyme-modulating\nOptimer\nRoyalty payments on product sales plus milestone and manufacturing revenues\nSecond licensing deal demonstrates commercial validation of\nOptimer\u00ae\nplatform\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences (\nNASDAQ: MRVI)\ncompany and global provider of specialty enzymes used in the life sciences sector, have entered into a licensing agreement for a developed Optimer\u00ae for use in hot-start PCR applications.\nThis binder acts as a precise molecular control mechanism in hot-start DNA amplification, a widely used laboratory technique in which the key enzyme is kept inactive at lower temperatures and only switches on when heated. This prevents unwanted DNA copying early in the process, leading to much more accurate and reliable results in applications such as genetic testing, diagnostic assays, and library preparation for next-generation sequencing (NGS), the high-throughput technology that allows rapid and cost-effective analysis of millions of DNA fragments in parallel.\nAgreement advances product portfolio for both companies\nUnder the terms of the agreement, Aptamer grants Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer\u00ae in hot-start PCR and next-generation sequencing (NGS) applications within Alphazyme's own products and services. The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer\u00ae. Aptamer will manufacture the Optimer\u00ae for Alphazyme, providing quality assurance and supply chain security whilst generating additional manufacturing revenue.\nRapid progression from development to licence\nAptamer and Alphazyme originally signed a development agreement for the hot-start PCR Optimer\u00ae in June 2024, with delivery of the final product in December 2024. Alphazyme demonstrated successful performance in its laboratory tests, showing temperature-sensitive control of the enzyme's exonuclease and polymerase activities. The Optimer\u00ae achieves what typically requires two antibodies, offering performance enhancement and cost advantages.\nFollowing this success, a second Optimer\u00ae development programme for enzyme modulation has been initiated with Alphazyme to broaden the customer's product portfolio. This project has recently completed the development phase, with candidate molecules having been delivered to Alphazyme for internal testing with positive results in the customer's hands.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"\nWe are delighted to announce the signing of this licensing agreement with Alphazyme. This second\nenzyme modulation\nlicensing agreement validates both the technical performance and commercial appeal of Optimer\u00ae technology in the molecular biology market. One of the standout features is the ability of our product to replace two antibodies with a single product, offering significant performance and manufacturing advantages, which will drive further\nlicensing opportunities on successful technical validation of the second project.\n\"\nWe look forward to building on the relationship with Alphazyme through our ongoing development programmes, which will provide the opportunity for further licensing of our Optimer\u00ae technology.\n\"\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRQXLBLELLLFBB"
        },
        {
          "title": "Aptamer signs licensing agreement with Alphazyme",
          "announcement_date": "23rd Dec 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "23 Dec 2025 07:00\nRNS Number : 6368M\nAptamer Group PLC\n23 December 2025\n23 December 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAptamer signs licensing agreement with Alphazyme\nNon-exclusive OEM license for enzyme-modulating\nOptimer\nRoyalty payments on product sales plus milestone and manufacturing revenues\nSecond licensing deal demonstrates commercial validation of\nOptimer\u00ae\nplatform\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, and Alphazyme LLC (Alphazyme), a Maravai LifeSciences (\nNASDAQ: MRVI)\ncompany and global provider of specialty enzymes used in the life sciences sector, have entered into a licensing agreement for a developed Optimer\u00ae for use in hot-start PCR applications.\nThis binder acts as a precise molecular control mechanism in hot-start DNA amplification, a widely used laboratory technique in which the key enzyme is kept inactive at lower temperatures and only switches on when heated. This prevents unwanted DNA copying early in the process, leading to much more accurate and reliable results in applications such as genetic testing, diagnostic assays, and library preparation for next-generation sequencing (NGS), the high-throughput technology that allows rapid and cost-effective analysis of millions of DNA fragments in parallel.\nAgreement advances product portfolio for both companies\nUnder the terms of the agreement, Aptamer grants Alphazyme a non-exclusive licence for use of an enzyme-modulating Optimer\u00ae in hot-start PCR and next-generation sequencing (NGS) applications within Alphazyme's own products and services. The agreement provides worldwide rights to Alphazyme and includes royalty payments on sales of products, milestone payments, and a supply agreement for the manufacturing of the Optimer\u00ae. Aptamer will manufacture the Optimer\u00ae for Alphazyme, providing quality assurance and supply chain security whilst generating additional manufacturing revenue.\nRapid progression from development to licence\nAptamer and Alphazyme originally signed a development agreement for the hot-start PCR Optimer\u00ae in June 2024, with delivery of the final product in December 2024. Alphazyme demonstrated successful performance in its laboratory tests, showing temperature-sensitive control of the enzyme's exonuclease and polymerase activities. The Optimer\u00ae achieves what typically requires two antibodies, offering performance enhancement and cost advantages.\nFollowing this success, a second Optimer\u00ae development programme for enzyme modulation has been initiated with Alphazyme to broaden the customer's product portfolio. This project has recently completed the development phase, with candidate molecules having been delivered to Alphazyme for internal testing with positive results in the customer's hands.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"\nWe are delighted to announce the signing of this licensing agreement with Alphazyme. This second\nenzyme modulation\nlicensing agreement validates both the technical performance and commercial appeal of Optimer\u00ae technology in the molecular biology market. One of the standout features is the ability of our product to replace two antibodies with a single product, offering significant performance and manufacturing advantages, which will drive further\nlicensing opportunities on successful technical validation of the second project.\n\"\nWe look forward to building on the relationship with Alphazyme through our ongoing development programmes, which will provide the opportunity for further licensing of our Optimer\u00ae technology.\n\"\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRQXLBLELLLFBB"
        },
        {
          "title": "Licensing agreement with Twist Bioscience",
          "announcement_date": "16th Dec 2025",
          "release_time": "10:34 am",
          "source": "RNS",
          "content": "16 Dec 2025 10:34\nRNS Number : 7785L\nAptamer Group PLC\n16 December 2025\n16 December 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAptamer signs licensing agreement with Twist Bioscience\nNon-exclusive license for Optimer\u00ae binder targeting the next-generation sequencing market\nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, is pleased to announce a first licensing agreement with Twist Bioscience, a leading synthetic biology and genomics company.\nUnder the terms of the agreement, Aptamer has granted Twist Bioscience a non-exclusive license for use of a proprietary enzyme-modulating Optimer\u00ae binder in both existing and future hot-start PCR, a highly precise version of the standard DNA copying process, and next-generation sequencing (NGS) products.\nNGS represents a rapidly expanding market, driven by increasing applications across healthcare, agriculture, and research. The NGS market is expected to reach US$23.6bn by 2029, with a CAGR of 13.2%\n1\n. Twist Bioscience is a market leader in synthetic DNA and has established a strong position in NGS library preparation, making it an ideal partner for commercialising Aptamer's binder technology in this high-growth sector.\nThis\nOptimer\u00ae\ndevelopment project, completed in partnership with Twist Bioscience, was signed, delivered, and validated. The resulting enzyme-modulating Optimers provide precise, temperature-dependent control for both research and assays. In hot-start PCR applications, the\nOptimer\u00ae\nbinder demonstrates robust performance, eliminating the need for two separate antibody reagents typically required in alternative methods.\nUnder the agreement, Aptamer will supply the\nOptimer\u00ae\nbinder to Twist Bioscience. The partnership allows Aptamer to maximise value from its intellectual property and directly participate in the market success of products incorporating its\nOptimer\u00ae\ntechnology. Aptamer establishes long-term partnerships built on shared incentives and collaborative growth, ensuring sustained value creation from its innovative biotechnology assets.\nDr Arron Tolley, Chief Executive Officer of Aptamer Group, commented:\n\"This licensing agreement with Twist Bioscience represents a significant step forward in Aptamer's strategy to build a licensing-led revenue model. It validates the commercial potential of our binders in the NGS market and provides a structure that combines upfront payments with ongoing royalties, demonstrating how our platform can deliver sustainable and recurring income streams.\n\"By directly supplying Twist Bioscience with\nOptimer\u00ae\nreagents, we can ensure the high quality and performance standards while embedding our technology into their NGS portfolio. Twist Bioscience is recognised globally as a leader in synthetic DNA and sequencing tools, and its scale and established customer base provide an excellent route to market for our binders. With the NGS sector showing continued growth, this partnership positions Aptamer to participate in that growth alongside a proven market leader. We look forward to supporting Twist Bioscience in expanding its sequencing solutions and to building further licensing opportunities across our technology base.\"\n1.\nhttps://www.marketsandmarkets.com/Market-Reports/next-generation-sequencing-ngs-technologies-market-546.html\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nAbout Twist Bioscience\nhttps://www.twistbioscience.com\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGRGPGPWPUPAGUQ"
        },
        {
          "title": "Results of 2025 Annual General Meeting",
          "announcement_date": "27th Nov 2025",
          "release_time": "1:01 pm",
          "source": "RNS",
          "content": "27 Nov 2025 13:01\nRNS Number : 3251J\nAptamer Group PLC\n27 November 2025\n27 November 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nResults of 2025 Annual General Meeting\nAptamer Group plc\n(AIM: APTA), the\nleading developer of next-generation synthetic binders delivering innovation to the life science industry\n,\ntoday announces that the results of voting on the resolutions put to shareholders at its Annual General Meeting (AGM) held earlier today at\u00a011:00 am\u00a0at the offices of\u00a0Aptamer Group, Windmill House,\u00a0Innovation Way, York, YO23 1LR, all Resolutions were duly passed.\nFurther details of each of the resolutions are set out in the Notice of Meeting, which was sent to shareholders on 3 November 2025, and the full poll results will be made available on the Aptamer website later today.\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nRAGLDLFLEFLEFBK"
        },
        {
          "title": "AGM Statement",
          "announcement_date": "27th Nov 2025",
          "release_time": "7:00 am",
          "source": "RNS",
          "content": "27 Nov 2025 07:00\nRNS Number : 1754J\nAptamer Group PLC\n27 November 2025\n27 November 2025\nAptamer Group plc\n(\"Aptamer\", the \"Company\" or the \"Group\")\nAnnual General Meeting Statement\nAptamer Group plc\n(AIM: APTA), the\nleading developer of next-generation synthetic binders delivering innovation to the life science industry\n,\nwill hold its Annual General Meeting (AGM) at\u00a011:00 am\u00a0today at the offices of\u00a0Aptamer Group, Windmill House,\u00a0Innovation Way, York, YO10 5BR.\nDr Adam Hargreaves, Non-Executive Chairman, will provide the following statement:\n\"Since becoming Chairman last year, I am delighted to report a period of sustained commercial momentum and strategic progress. Lately, we have announced a series of significant contract wins, including partnerships and repeat business orders with three of the top 10 global pharmaceutical companies. This has contributed to an order book of signed contracts for FY26 of \u00a31.95 million with seven months of the year remaining. This provides the Board with great confidence that revenue will materially exceed the prior year's performance.\nThe consistent repeat business we have seen from top-tier pharmaceutical companies signals both the strategic potential and the increasing value being placed in our\nOptimer\u00ae\nplatform by leading pharmaceutical companies. We continue to focus on developing licensable assets and retaining intellectual property or commercialisation rights in areas of high value, positioning the Group to capture significant long-term value through licensing and royalties. In our journey to reach a significant and critical value inflection point, it is pleasing to see Aptamer cover increasing levels of its operating cost base.\nAdding to our opportunity landscape, we launched a Biomarker Discovery Service in August 2025, enhancing our capabilities to attract additional fee-for-service revenues in high value areas. We have also advanced key collaborations, including a therapeutic agreement with Invizius and a water-borne pathogen detection project with Metir plc.\nTo support this growth, we successfully raised \u00a31.8 million through a July 2025 placing, at a modest discount, providing capital for operational expansion and Research and Development. Considering the solid progress, the Group achieved an impressive uplift in share price and total market cap over this past 12 months, positioning itself firmly as an established small-cap life-sciences company listed on the AIM market. The Board firmly believes that the growth trajectory has only just commenced and is encouraged by myriad opportunities available within the field and our increasing repeat business pipeline.\nLooking ahead, we remain confident in our growing portfolio of licensable assets and securing licensing deals with near-term royalties, which will allow the Group to start building passive income streams. With ongoing investor engagement through webinars and events, and a focus on intellectual property retention, future licensing and success-based repeat business, we are well-positioned to drive shareholder value.\nThe Board looks forward to updating shareholders on further progress in due course.\"\n\u200b\nThe AGM will not provide any new material information. Results of the AGM will be announced to the London Stock Exchange and placed on the Group's website, in the usual way, as soon as practicable after the conclusion of the AGM.\n- Ends -\nFor further information, please contact:\nAptamer Group plc\nDr Arron Tolley, Chief Executive Officer\n+44 (0) 1904 217 404\nSPARK Advisory Partners Limited - Nominated Adviser\nAndrew Emmott\n+44 (0) 20 3368 3550\nTurner Pope Investments (TPI) Limited - Broker\nAndrew Thacker\u202f/ Guy McDougall\n+44 (0) 20 3657 0050\nNorthstar Communications\u00a0Limited - Investor Relations\nSarah Hollins\n+44 (0) 113 730 3896\nAbout Aptamer Group\nAptamer Group is a\nleading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group\ndevelops Optimer\u00ae binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like\u00a0high stability, reliable performance, and lower costs\u00a0compared to traditional antibodies.\nAptamer operates a fee-for-service business\u00a0in the US$210 billion\nmarket for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer\u00ae assets with partners, aiming for future licensing revenue.\nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\nTo register for news alerts by email go to\nhttps://aptamergroup.com/investors/investor-news-email-alerts/\nForward-Looking Statements\nThis announcement contains forward-looking statements. These relate to future events or performance and include statements about expected revenues, earnings, cash flows, business strategy and growth prospects. Forward-looking statements involve risks and uncertainties. Actual results may differ materially from those expressed or implied due to factors including economic conditions, competition, regulatory changes and industry trends. Past performance is not a guide to future performance. No statement in this announcement constitutes a profit forecast or profit estimate. The Company undertakes no obligation to update these statements, except as required by law or by any appropriate regulatory authority.\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact\nrns@lseg.com\nor visit\nwww.rns.com\n.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our\nPrivacy Policy\n.\nEND\nAGMBFBLTMTMTBAA"
        }
      ],
      "themes": [
        "drilling"
      ]
    },
    "social": {
      "has_data": true,
      "buzz_level": "HIGH",
      "post_count": 379,
      "sentiment_breakdown": {
        "positive": 0.0,
        "neutral": 100.0,
        "negative": 0.0
      }
    },
    "trends": {
      "has_data": true,
      "current_interest": 0,
      "momentum_score": -52.31,
      "trend_direction": "DOWN",
      "intelligence_signal": "DEAD_TICKER",
      "activity_level": "DEAD"
    },
    "volatility": {
      "atr_normalized": null,
      "stddev_20d": null
    },
    "risk_flags": {
      "split_risk_level": "NONE",
      "halt_risk": "NONE",
      "penny_stock_risk": "NONE"
    }
  },
  "ai_insights": {
    "available": false,
    "reason": "LLM module not loaded or analysis failed"
  },
  "scoring_breakdown": {
    "apex_factors": [
      "Technical quality: +11 (AI_Technical_Score=9.0/20)",
      "Drawdown reversion potential: +17 (Drawdown_Pct=85.5%)",
      "Volume confirmation: +10 (Relative_Volume=2.1)",
      "Pattern reliability: +5 (Rally_Count=2.0)",
      "Upside history: +12 (best_rally_pct=465%)"
    ],
    "technical_score": {
      "points": 11,
      "ai_score": 9.0,
      "reason": "AI Technical Score 9.0/20 translates to 11/25 points"
    },
    "drawdown_score": {
      "points": 17,
      "drawdown_pct": 85.53,
      "reason": "Drawdown of 85.5% gives 17/20 points"
    },
    "volume_score": {
      "points": 10,
      "rel_volume": 2.15,
      "reason": "Relative volume 2.15x gives 10 points"
    },
    "pattern_score": {
      "points": 5,
      "rally_count": 2.0,
      "reason": "2.0 historical rallies gives 5/15 points"
    },
    "upside_score": {
      "points": 12,
      "best_rally_pct": 465.22,
      "reason": "Best rally of 465% gives 12/20 points"
    },
    "penalties": {
      "total": 0,
      "items": []
    }
  },
  "reasons_buy_sell": {
    "reasons_to_buy": [
      {
        "reason": "Early stage positioning offers best R:R if catalysts appear",
        "tag": "MED",
        "evidence": [
          "timing_regime=EARLY_BUILD",
          "current_return_pct=323.9%"
        ]
      },
      {
        "reason": "Proven winner - previously hit lock-in target",
        "tag": "MED",
        "evidence": [
          "lock_in_reached=True"
        ]
      }
    ],
    "reasons_to_sell": [
      {
        "reason": "Triangulation not loaded (RNS/social/trends missing)",
        "tag": "HIGH",
        "evidence": [
          "analysis_mode=HISTORICAL_ONLY",
          "confidence_capped_at_65"
        ]
      },
      {
        "reason": "Stale signal - not for active trading",
        "tag": "HIGH",
        "evidence": [
          "status=historical"
        ]
      }
    ]
  },
  "trade_plan": {
    "trader_plan": {
      "style": "Watch / Starter",
      "action": "Wait for base + catalyst confirmation; starter position only",
      "sizing": "0-1% until CONFIRMED",
      "risk": "Invalidation = breaks recent lows / dilution / suspension",
      "profit_taking": "Scale out 25% at +15%, 25% at +50%, runner above"
    },
    "investor_plan": {
      "allowed": false,
      "thesis_conditions": "Unlock after AI triangulation + CONFIRMED timing",
      "hold_window": "N/A",
      "risk_management": "N/A"
    }
  },
  "exhaustion": {
    "regime": "EARLY_BUILD",
    "run_multiple": 0.7,
    "current_run_pct": 323.91,
    "avg_historical_run_pct": 465.22
  },
  "history_snapshot": {
    "previous_report_date": null,
    "score_change": null,
    "confidence_change": null,
    "new_events_count": 0,
    "new_rns_titles": []
  },
  "commentary": {
    "executive_summary": "This report runs in HISTORICAL-ONLY mode: triangulation (RNS/social/trends) not loaded. The setup shows EARLY_BUILD timing with 55/100 APEX score. Historical data shows 2 rallies averaging 465% upside. Current position: +323.9%. Your edge comes from waiting for AI Engine confirmation instead of blind entry.",
    "bull_case": [
      "Early regime often offers best risk/reward"
    ],
    "bear_case": [
      "Monitor for breakdown signals"
    ],
    "timing_translation": "Early accumulation phase. Watch for confirmation before committing size.",
    "confidence_explained": "Confidence 40/100 reflects full data quality with triangulation loaded."
  },
  "data_quality": {
    "sources_present": {
      "snapshot_json": false,
      "daily_enrichment_row": true,
      "historical_profile": false,
      "metadata": true,
      "triangulation_events": true,
      "ai_insights": false
    },
    "missing_data": [
      "AI insights from Groq LLM"
    ],
    "confidence_impact": "HIGH",
    "disclaimer": "Data provided as-is. Not financial advice. AIM micro-caps carry significant volatility risk."
  }
}